Promising combo aims to wipe out esophageal cancer before surgery
NCT ID NCT07595770
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding adalimumab to standard chemotherapy and radiation before surgery can help eliminate esophageal cancer more effectively. About 37 adults with resectable esophageal squamous cell carcinoma will receive this combination. The main goal is to see how many patients have no cancer cells left at the time of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return